[The first results of treatment for adult acute myeloid leukemia according to the AML-01.10 protocol of the Research Group of the Hematology Centers of Russia].

Author: AnchukovaL V, BondarenkoS N, GavrilovaL V, IalykomovI V, KaplanovK D, KaporskaiaT S, KliasovaG A, KokhnoA V, KondakovaE V, KonstantinovaT S, KravchenkoS K, KulikovS M, Kuz'minaL A, LapinV A, MoskovV I, ParovichnikovaE N, PristupaA S, RyzhkoV V, SamoĭlovaO S, SavchenkoV G, ShaforostovaI I, SokolovA N, TroitskaiaV V, VolodichevaE M, ZagoskinaT P

Overview

A multicenter randomized trial in Russia using high-dose anthracycline antibiotics in induction/consolidation for adult acute myeloid leukemia (AML) showed promising results. The protocol achieved a high complete remission rate of 74.6% and demonstrated acceptable toxicity.

Paper Details　

Original Abstract of the Article :

AIM: To give the preliminary results of the AML-01.10 Russian multicenter randomized trial to treat adult acute myeloid leukemia (AML), the basic principle of which is to use high-dose anthracycline antibiotics in induction/consolidation. SUBJECTS AND METHODS: By December 2011, 145 patients with AM...See full text at original site

Dr.Camel's Paper Summary Blog

AML-01.10: A New Oasis for Acute Myeloid Leukemia

This study presents the initial results of a multicenter randomized trial for adult acute myeloid leukemia (AML), a serious type of blood cancer. Imagine a camel facing a dangerous storm in the desert, needing immediate intervention to survive. AML is like that storm, threatening the body's ability to produce healthy blood cells. This study explores a new treatment protocol designed to improve outcomes for patients with AML.

The researchers conducted a trial involving 145 patients with AML, comparing a new treatment protocol, AML-01.10, to existing standard therapies. The AML-01.10 protocol involved using high-dose anthracycline antibiotics in the induction and consolidation phases of treatment.

The initial results of the trial showed that the AML-01.10 protocol was effective in achieving complete remission in a significant proportion of patients. The protocol also demonstrated acceptable levels of toxicity. This suggests that the AML-01.10 protocol could be a valuable treatment option for patients with AML, offering a potential oasis in the storm of this challenging disease.

Hope for a Brighter Future: Navigating the Storm of AML

The study's findings offer hope for patients with AML, suggesting that the AML-01.10 protocol could be a valuable treatment option.

Dr. Camel's Conclusion

Dr. Camel believes that this research represents a significant step forward in the treatment of AML, offering a potential lifeline for patients battling this serious disease. The study's findings underscore the importance of ongoing research and development of new treatment protocols to improve outcomes for patients with AML. Dr. Camel encourages patients to seek out the latest information and treatment options available, working with their healthcare providers to navigate the challenging journey of cancer treatment with greater hope and resilience. Remember, a journey through the storm of illness requires a strong support system, a compassionate team, and a resolute spirit to reach a brighter and healthier shore.